American Regent Announces Results From Phase 3 HEART-FID Tri

American Regent, Inc., a Daiichi Sankyo Group company, today announced results from the phase 3 HEART-FID trial of INJECTAFER® (ferric carboxymaltose injection) for the treatment of iron deficiency in adult heart

Related Keywords

United States , Ohio , New York , American , Robert Mentz , Ravi Tayi , Drug Administration , Daiichi Sankyo Inc , European Society Of Cardiology Congress , Daiichi Sankyo Group , American Regent Inc , York Heart Association , Member Of The Duke Clinical Research Institute , Laboratory Test Alterations , Adverse Drug Events To American Regent Inc , American Regent , Hot Line , European Society , Cardiology Congress , New England Journal , Associate Professor , Duke University School , Duke Clinical Research Institute , Clinical Lead , Chief Medical Officer , New York Heart Association , Safety Information , Iron Deficiency , Heart Failure , Adverse Drug Events , Prescribing Information , Ferric Carboxymaltose , Daiichi Sankyo , Basking Ridge ,